Activated prothrombin complex concentrate (APCC)-mediated activation of factor (F)VIII in mixtures of FVIII and APCC enhances hemostatic effectiveness

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 5, 2013, Pages 902-910

  Yada, K ^a   Nogami, K ^a   Ogiwara, K ^a   Shima, M ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Activation analysis; Blood coagulation; Factor IX, factor VII, factor X prothrombin drug combination; Factor VIII human; Hemophilia A; Inhibitors

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 7A INHIBITOR; BLOOD CLOTTING FACTOR 8; EPITOPE; HIRUDIN; PHOSPHOLIPID; RECOMBINANT BLOOD CLOTTING FACTOR 7A; THROMBOPLASTIN;

ANTIBODY TITER; ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; HEMOSTASIS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN DEGRADATION;

AUTOANTIBODIES; COMPLEX MIXTURES; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FACTOR VIII; HEMOSTASIS; HUMANS; PROTEOLYSIS; PROTHROMBIN;

EID: 84877905556     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12197     Document Type: Article

References (20)

1. Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
2. Hoyer LW. The factor VIII complex: structure and function. Blood 1981; 58: 1-13.
3. Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-12.
4. Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-5.
5. Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haemotologica 2000; 85: 7-13.
6. Gawryl MS, Hoyer LW. Inactivation of factor VIII coagulant activity by two different types of human antibodies. Blood 1982; 60: 1103-9.
7. Prescott R, Nakai H, Saenko EL, Scharrer I, Nilsson IM, Humphries JE, Hurst D, Bray G, Scandella D. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Blood 1997; 89: 3663-71.
8. Zhong D, Saenko EL, Shima M, Felch M, Scandella D. Some human inhibitor antibodies interfere with factor VIII binding to factor IX. Blood 1998; 92: 136-42.
9. Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-42.
10. Nogami K, Shima M, Hosokawa K, Nagata M, Koide T, Saenko EL, Tanaka I, Shibata M, Yoshioka A. Factor VIII C2 domain contains the thrombin-binding site responsible for thrombin-catalyzed cleavage at Arg1689. J Biol Chem 2000; 275: 25774-80.
11. Nogami K, Shima M, Hosokawa K, Suzuki T, Koide T, Saenko EL, Scandella D, Shibata M, Kamisue S, Tanaka I, Yoshioka A. Role of factor VIII C2 domain in factor VIII binding to factor Xa. J Biol Chem 1999; 274: 31000-7.
12. Matsumoto T, Nogami K, Ogiwara K, Shima M. A putative inhibitory mechanism in the tenase complex responsible for loss of coagulation function in acquired hemophilia A patients with anti-C2 autoantibodies. Thromb Haemost 2012; 107: 288-301.
13. Fay PJ, Scandella D. Human inhibitor antibodies specific for the factor VIII A2 domain disrupt the interaction between the subunit and factor IXa. J Biol Chem 1999; 274: 29826-30.
14. Soeda T, Nogami K, Matsumoto T, Ogiwara K, Shima M. Mechanisms of factor VIIa-catalyzed activation of factor VIII. J Thromb Haemost 2010; 8: 2494-503.
15. Yada K, Nogami K, Ogiwara K, Shibata M, Shima M. Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalysed activation and inactivation of factor VIII. Thromb Haemost 2011; 105: 989-98.
16. Klintman J, Astermark J, Berntorp E. Combination of FVIII and bypassing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma. Br J Haematol 2010; 151: 381-6.
17. Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW. A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 1992; 67: 665-71.
18. Griffin BD, Micklem LR, McCann MC, James K, Pepper DS. The production and characterisation of a panel of ten murine monoclonal antibodies to human procoagulant factor VIII. Thromb Haemost 1986; 55: 40-6.
19. Mimms LT, Zampighi G, Nozaki Y, Tanford C, Reynolds JA. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-40.
20. Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17-20.